As recently reported, an NGS profiling including HR genes (BARD1, BRIP1, PALB2, RAD51C, and RAD51D) could improve the rate of tumor with HRD by 5–6%, identifying patients who may mostly benefit from PARPi therapy [29]. This evidence concerns the gene RAD51C and neoplasm.